FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224229807> ?p ?o ?g. }

• W4224229807 endingPage "1111" @default.
• W4224229807 startingPage "1089" @default.
• W4224229807 abstract "Diabetic retinopathy (DR) is the most common microangiopathic complication of diabetes mellitus, representing a major cause of visual impairment in developed countries. Proliferative DR (PDR) represents the last stage of this extremely complex retinal disease, characterized by the development of neovascularization induced by the abnormal production and release of vascular endothelial growth factor (VEGF). The term VEGF includes different isoforms; VEGF-A represents one of the most important pathogenic factors of DR. Anti-VEGF intravitreal therapies radically changed the outcome of DR, due to combined anti-angiogenic and anti-edematous activities. Nowadays, several anti-VEGF molecules exist, characterized by different pharmacological features and duration. With respect to PDR, although anti-VEGF treatments represented a fundamental step forward in the management of this dramatic complication, a big debate is present in the literature regarding the role of anti-VEGF as substitute of panretinal photocoagulation or if these two approaches may be used in combination. In the present review, we provided an update on VEGF isoforms and their role in DR pathogenesis, on current anti-VEGF molecules and emerging new drugs, and on the current management strategies of PDR. There is an overall agreement regarding the relative advantage provided by anti-VEGF, especially looking at the management of PDR patients requiring vitrectomy, with respect to laser. Based on the current data, laser approaches might be avoided when a perfectly planned anti-VEGF therapeutic strategy can be adopted. Conversely, laser treatment may have a role for those patients unable to guarantee enough compliance to anti-VEGF injections.Key messagesVEGF increased production, stimulated by retinal hypoperfusion and ischaemia, is a major pathogenic factor of neovascular complication onset in diabetic retinopathy and of DR stages progression.Nowadays, several anti-VEGF molecules are available in clinical practice and other molecules are currently under investigation. Each anti-VEGF molecule is characterized by different targets and may interact with multiple biochemical pathways within the eye.All the data agreed in considering anti-VEGF molecules as a first line choice for the management of diabetic retinopathy. Laser treatments may have a role in selected advanced cases and for those patients unable to guarantee enough compliance to intravitreal treatments schemes." @default.
• W4224229807 created "2022-04-26" @default.
• W4224229807 creator A5008263008 @default.
• W4224229807 creator A5025154230 @default.
• W4224229807 creator A5056909319 @default.
• W4224229807 date "2022-04-22" @default.
• W4224229807 modified "2023-10-05" @default.
• W4224229807 title "VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy" @default.
• W4224229807 cites W1236607721 @default.
• W4224229807 cites W1545259384 @default.
• W4224229807 cites W1547832571 @default.
• W4224229807 cites W1559170621 @default.
• W4224229807 cites W1731074416 @default.
• W4224229807 cites W1783580437 @default.
• W4224229807 cites W1786299986 @default.
• W4224229807 cites W1802218256 @default.
• W4224229807 cites W1862433354 @default.
• W4224229807 cites W1872281589 @default.
• W4224229807 cites W188190672 @default.
• W4224229807 cites W1887310754 @default.
• W4224229807 cites W1900738367 @default.
• W4224229807 cites W1963128268 @default.
• W4224229807 cites W1963831779 @default.
• W4224229807 cites W1964677780 @default.
• W4224229807 cites W1968484708 @default.
• W4224229807 cites W1972102480 @default.
• W4224229807 cites W1972240224 @default.
• W4224229807 cites W1973358829 @default.
• W4224229807 cites W1976704017 @default.
• W4224229807 cites W1980725734 @default.
• W4224229807 cites W1985043086 @default.
• W4224229807 cites W1989995924 @default.
• W4224229807 cites W1991958278 @default.
• W4224229807 cites W1998400323 @default.
• W4224229807 cites W2004320289 @default.
• W4224229807 cites W2004918005 @default.
• W4224229807 cites W2005076995 @default.
• W4224229807 cites W2009964074 @default.
• W4224229807 cites W2010599103 @default.
• W4224229807 cites W2011046688 @default.
• W4224229807 cites W2012043490 @default.
• W4224229807 cites W2013561902 @default.
• W4224229807 cites W2014878084 @default.
• W4224229807 cites W2017195546 @default.
• W4224229807 cites W2017879489 @default.
• W4224229807 cites W2019061836 @default.
• W4224229807 cites W2023052504 @default.
• W4224229807 cites W2024206845 @default.
• W4224229807 cites W2030504942 @default.
• W4224229807 cites W2036712095 @default.
• W4224229807 cites W2037943855 @default.
• W4224229807 cites W2042362462 @default.
• W4224229807 cites W2043630178 @default.
• W4224229807 cites W2046507292 @default.
• W4224229807 cites W2049292409 @default.
• W4224229807 cites W2057697484 @default.
• W4224229807 cites W2060698866 @default.
• W4224229807 cites W2063709616 @default.
• W4224229807 cites W2065863629 @default.
• W4224229807 cites W2075843683 @default.
• W4224229807 cites W2077129920 @default.
• W4224229807 cites W2079899325 @default.
• W4224229807 cites W2083157562 @default.
• W4224229807 cites W2085277615 @default.
• W4224229807 cites W2086256951 @default.
• W4224229807 cites W2087899702 @default.
• W4224229807 cites W2089123613 @default.
• W4224229807 cites W2091989599 @default.
• W4224229807 cites W2093498435 @default.
• W4224229807 cites W2095215861 @default.
• W4224229807 cites W2102463203 @default.
• W4224229807 cites W2104034463 @default.
• W4224229807 cites W2114112168 @default.
• W4224229807 cites W2114234975 @default.
• W4224229807 cites W2118548020 @default.
• W4224229807 cites W2119803906 @default.
• W4224229807 cites W2123123877 @default.
• W4224229807 cites W2125014313 @default.
• W4224229807 cites W2125130429 @default.
• W4224229807 cites W2140362791 @default.
• W4224229807 cites W2142218571 @default.
• W4224229807 cites W2146953551 @default.
• W4224229807 cites W2149471545 @default.
• W4224229807 cites W2151056029 @default.
• W4224229807 cites W2159241628 @default.
• W4224229807 cites W2161279821 @default.
• W4224229807 cites W2161588304 @default.
• W4224229807 cites W2170367762 @default.
• W4224229807 cites W2171845476 @default.
• W4224229807 cites W2173144648 @default.
• W4224229807 cites W2178156144 @default.
• W4224229807 cites W2193621263 @default.
• W4224229807 cites W2233259956 @default.
• W4224229807 cites W2316481043 @default.
• W4224229807 cites W2511422297 @default.
• W4224229807 cites W2524064376 @default.
• W4224229807 cites W2526112735 @default.
• W4224229807 cites W2527984285 @default.

• next